Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related disease. IgG4-RD is a chronic and debilitating immune-mediated inflammatory condition that can affect multiple organs. The FDA granted Breakthrough Therapy Designation to Uplizna for the treatment of IgG4-RD, recognizing the high unmet medical need in this serious condition and the medicine’s potential to benefit patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Strong Market Position and Growth Potential Justify Buy Rating
- Senator Slams Pfizer (PFE) for “Biggest Tax-Dodging Scheme in Pharma History”
- Quantinuum Shakes Up Quantum Computing with Giant Backers and Big Moves
- Cathie Wood’s ARK Invest Snaps Up Tesla Stock (TSLA) amid 42% Price Drop
- BMO says Eylea court decision ‘modest negative’ for Regeneron